Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Interactions with Dolutegravir

Tuesday 15 October 2013

Dolutegravir (Tivicay®), an integrase inhibitor, was licensed in America a few months ago and is awaiting a European marketing authorisation. Based on information given in the US Prescribing Information (and other metabolic/elimination data), interactions with dolutegravir and comedications have now been added to web and app versions of the charts. Revisions may be required once the European Summary of Product Characteristics is available.
 
The printable versions of the charts and the treatment selectors will be updated in the next few weeks.
SPONSORS
Sponsor logo janssen Sponsor logo gilead Sponsor logo msd Sponsor logo viiv
EDITORIAL SPONSORS
Hiv  glasgow 2018 cmyk logo Eacs logo 2014 Bhiva 2018 Basel text
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017 rcp-excellence-patient-care-awards-2017 building_better_healthcare_awards_2016